Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +48.85%
#3 Non-Playable Coin Non-Playable Coin +23.47%
#4 龙虾 (Lobster) 龙虾 (Lobster) +22.08%
#5 Pons Pons +21.99%
#6 OriginTrail OriginTrail +19.87%
#7 Zora Zora +18.45%
#8 ApeX ApeX +17.92%
#9 Morpho Morpho +17.90%
#10 UnifAI Network UnifAI Network +16.17%
Coin of the day
Smilek to the Bank Smilek to the Bank
Настройки
Язык
Pусский
Валюта
USD
Тема
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Ранг среди акций #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Цена акции
$1.11
Последняя синхронизация: 2026-08-21
Рыночная капитализация
$100.55M
Изменение (1 день)
-7.69%
Изменение (1 год)
-7.17%
Страна
TW
Торговля Senhwa Biosciences, Inc. (6492)

Категория

Healthcare
История цены акций Senhwa Biosciences, Inc. (6492)
Наивысшая цена закрытия: $1.20 2026-08-01

Наименьшая цена закрытия: $3.18 2014-12-01
История цены акций Senhwa Biosciences, Inc. с 2014 по 2026
Годовая динамика цены акций
Год Результативность
2026 (TTM) 9.09%
2025 -0.30%
2024 -22.02%
2023 -15.51%
2022 -44.72%
2021 -53.30%
2020 275.09%
2019 -9.86%
2018 3.54%
2017 -60.65%
2016 1.24%
2015 74.07%
2014 0.00%
Цена акций похожих компаний или конкурентов
Компания Цена акций Изменение 1г% Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.70 -15.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH